6:44 PM
 | 
Feb 01, 2007
 |  BC Extra  |  Clinical News

AGI misses endpoints in two trials

AGI (ISE:A9I; LSE:AGI) missed the primary endpoints in a pair of Phase II trials on Thursday. In a trial to treat functional dyspepsia, preliminary...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >